✦ LIBER ✦

A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance

✍ Scribed by Verweij, J; Herweijer, H; Oosterom, R; van der Burg, MEL; Planting, ASTh; Seynaeve, C; Stoter, G; Nooter, K

Book ID: 109836614
Publisher: Nature Publishing Group
Year: 1991
Tongue: English
Weight: 744 KB
Volume: 64
Category: Article
ISSN: 0007-0920
DOI: 10.1038/bjc.1991.307

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study to determine the abilit

A phase II study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study)

✍ Stebbing, J; Harrison, M; Glynne-Jones, R; Bridgewater, J; Propper, D 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 100 KB

Evaluation of Cisplatin and Cyclosporin

Evaluation of Cisplatin and Cyclosporin A in Recurrent Platinum-Resistant Ovarian Cancer: A Phase II Study of the Gynecologic Oncology Group

✍ Alberto Manetta; John A. Blessing; Jean A. Hurteau 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 29 KB

Phase II study of a triplet regimen in a

Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil

✍ Guglielmi, A; Barni, S; Zaniboni, A; Pella, N; Belvedere, O; Beretta, G D; Gross 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 103 KB

133 A phase II study of oxaliplatin, cap

133 A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer

✍ N. Fernando; M. Morse; G. Blobe; L. Sutton; L. Odogwu; W. Honeycutt; M. Bauer; M 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 144 KB

Phase I study of cinchonine, a multidrug

Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes

✍ Solary, E; Mannone, L; Moreau, D; Caillot, D; Casasnovas, R-O; Guy, H; Grandjean 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 151 KB

The effects of gefitinib in tamoxifen-re

The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: A phase II study

✍ Eleanor Gutteridge; Amit Agrawal; Robert Nicholson; Kwok Leung Cheung; John Robe 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 366 KB

## Abstract Estrogen receptor (ER)‐positive acquired tamoxifen‐resistant (TAM‐R) MCF‐7 breast cancer cell lines exhibit epidermal growth factor receptor (EGFR) expression/signaling and are growth‐inhibited by gefitinib (IRESSA). We examined the effect of gefitinib on ER‐positive TAM‐R and ER‐negati